AxoGen
Developing technologies for peripheral nerve regeneration and repair.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | $41.0m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 13 % | 9 % | 15 % | 18 % | 17 % | 16 % | 17 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (16 %) | (18 %) | (10 %) | 2 % | 13 % | 17 % | 24 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (21 %) | (21 %) | (14 %) | (5 %) | (2 %) | 4 % | 10 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 19 % | 20 % | 18 % | 15 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
AxoGen, Inc. (NASDAQ: AXGN) operates as a specialized medical technology firm focused on developing and commercializing surgical solutions for peripheral nerve repair. The company was founded in 2002 by Jamie Grooms, John P. Engels, and University of Florida neuroscientist David Muir, stemming from research conducted at the University of Florida and the University of Texas at Austin. This research aimed to address the limitations of traditional nerve repair, which often required a second surgery and could result in lasting damage. AxoGen was established in Alachua, Florida, within the Sid Martin Biotechnology Incubator, to bring these new technologies to market. A significant milestone was achieved in 2013 when the company went public with an initial public offering (IPO), raising $18 million.
The company’s business model centers on the direct sale of its product portfolio to hospitals and surgical centers. This portfolio targets a market opportunity estimated to exceed $2.7 billion in the U.S. for peripheral nerve damage repair. The client base primarily consists of reconstructive plastic surgeons, hand surgeons, and oral and maxillofacial surgeons. Revenue is generated directly from the sale of its products, with reported revenues of $110.2 million from its direct sales force in 2023. For fiscal year 2024, the company projects revenues between $176.0 million and $179.0 million.
AxoGen offers a comprehensive suite of products for peripheral nerve repair. Its cornerstone product, the Avance® Nerve Graft, is a processed human nerve allograft for bridging gaps in severed nerves, eliminating the need for a second surgical site. Other key products include the Axoguard Nerve Connector®, a coaptation aid for tensionless nerve repair; the Axoguard Nerve Protector®, which wraps and shields injured nerves; and the Axoguard Nerve Cap®, designed to protect nerve ends and reduce neuroma formation. These products are designed to provide surgeons with clinically proven and economically effective solutions to restore nerve function and improve patients' quality of life.
Keywords: peripheral nerve repair, nerve regeneration, surgical solutions, medical technology, Avance Nerve Graft, nerve allograft, Axoguard, reconstructive surgery, hand surgery, oral surgery, nerve damage, tissue grafts, regenerative medicine, neurosurgery, surgical devices, neuroma treatment, nerve protection, biotechnology, medical devices, AXGN